Clinical Trials

Title   BMS 209-812
Principal Investigator/ Physician   Thaddeus Beeker, MD
Protocol┬áNo.   BMS 209-812
Open Date   10/12/2017
Gender   Both
Cancer Site   Hodgkin Lymphoma
Status   Closed to Enrollment
Sponsor   Bristol-Myers Squibb
Contact Email   MCI Clinical Trials
Summary  

Protocol Title:  A Study of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Patients With Advanced Stage Classical Hodgkin Lymphoma, Who Are Relapsed/ Refractory or Who Are Not Eligible for Autologous Stem Cell Transplant, (CheckMate 812)

 

Inclusion Criteria: Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1; Participants must have a pathologic diagnosis of classical Hodgkin lymphoma (cHL) who are relapsed or refractory with one of the following: 1) Autologous stem cell transplant (ASCT) ineligible patients; 2) Patients after failure of ASCT; Must have at least one lesion that is > 15 mm (1.5 cm) in the longest diameter and avid by Fluoro Deoxy Glucose (FDG) Positron Emission Tomography (PET) scan.

 

Exclusion Criteria: Known central nervous system lymphoma; Participants with nodular lymphocyte-predominant Hodgkin lymphoma (HL); Participants with known history of pancreatitis or progressive multifocal leukoencephalopathy (PML)

 

Clinical Trials. Gov Link: https:https://clinicaltrials.gov/ct2/show/NCT03138499?term=209-812&rank=1//clinicaltrials.gov/ct2/show/NCT03138499?term=209-812&rank=1

Email Newsletters

Connect With Us